Skyrocketing Prices Push Americans to Create Their Own Weight-Loss Drugs
San Francisco: High costs of obesity medicines are driving Americans to a growing "gray market," where individuals make their own weight-loss drugs using cheap, unregulated active ingredients shipped from China. These substances, often labeled as "research materials," are purchased online and mixed into dosages by users themselves.
Missouri resident Amy Spencer, 50, is among those turning to this market. Spending just $50 a month, she mixes her own drugs using ingredients like tirzepatide, the key compound in Eli Lilly's Zepbound, saving up to 90% compared to branded treatments.
The demand for affordable alternatives surged after an FDA ruling barred U.S. compounding pharmacies from selling cheaper obesity medications. Imports of unregistered active ingredients from China rose by 44% in January 2025, according to the Partnership for Safe Medicines. Buyers frequently use platforms like Reddit and Telegram, exchanging advice on sourcing, shipping, and testing.
However, experts warn of severe risks. Unregulated substances may lack sterility and purity, leading to potential contamination. Some users have reported health issues due to incorrect dosages. Pharmaceutical giants like Novo Nordisk and Lilly are actively filing lawsuits and urging regulators to crack down on the illegal market.
With nearly three-quarters of U.S. adults overweight or obese, many are desperate for affordable solutions. Spencer, who has lost 24 pounds, says, "This medicine has changed my life. It's cheap, and it works."
Looking for chemical products? Let suppliers reach out to you!
2026-07-13
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
India Targets Fake Drug Packaging
Recommend Reading
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
India Raises Cancer Drug Price Caps by 50%
-
Premium Global Chemical Sourcing Requests (15-19 Sep 2025)
-
Taekwang Group Establishes SIL Cosmetics Division, Targeting the Korean and Global Markets
-
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
Industry inventory accumulation pushes acrylonitrile prices to five-year low in China
-
This Week, the Price of Polyester Bottle Chips First Increased and Then Decreased, Falling Within the Week